{"denoms":[{"counts":[{"groupId":"BG000","value":"432"},{"groupId":"BG001","value":"188"},{"groupId":"BG002","value":"217"},{"groupId":"BG003","value":"837"}],"units":"Participants"}],"groups":[{"description":"Participants received 40 mg cabozantinib oral tablets once daily + 1200 mg IV infusion of atezolizumab once every 3 weeks for up to 38 months.","id":"BG000","title":"Experimental Arm: Cabozantinib + Atezolizumab"},{"description":"Participants received 60 mg cabozantinib oral tablets once daily for up to 38 months.","id":"BG001","title":"Single-Agent Cabozantinib"},{"description":"Participants received 400 mg sorafenib oral tablets twice daily for up to 38 months.","id":"BG002","title":"Control Arm: Sorafenib"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"234"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"112"},{"groupId":"BG003","value":"443"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"198"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"105"},{"groupId":"BG003","value":"394"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"133"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"360"},{"groupId":"BG001","value":"158"},{"groupId":"BG002","value":"186"},{"groupId":"BG003","value":"704"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"78"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"352"},{"groupId":"BG001","value":"158"},{"groupId":"BG002","value":"183"},{"groupId":"BG003","value":"693"}]}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"66"}]}],"title":"Not Reported"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"127"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"72"},{"groupId":"BG003","value":"263"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"14"}]}],"title":"Black/African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"217"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"111"},{"groupId":"BG003","value":"423"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"137"}]}],"title":"Other than specified"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The Intent-to-Treat (ITT) population consisted of all participants who were randomized to any of the three study treatment arms, regardless of whether they received any study treatment."}